Abstract: This invention relates to a depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analog reverse transcriptase inhibitor, wherein the silica hydrogel composite is obtainable by mixing silica particles comprising said nucleotide or nucleoside analog reverse transcriptase inhibitor and having a maximum diameter of ?1 000 ?m, as such or as a suspension, with silica sol wherein the hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection. The present invention also relates to use of the depot formulation for treatment of chronic viral infections and prevention of chronic viral reinfection. The present invention further relates to a prefilled syringes comprising said depot formulation.

Abstract: A method for preparing a sol-gel derived SiO2 having a very fast bioresorption rate where a sol-gel derived SiO2 is prepared from a sol comprising water, an alkoxide or inorganic silicate and a lower alcohol using a mineral acid or a base as a catalyst and the sol is aged and dried. The method uses a pH from 1.5 to 2.5, a molar ratio of water to the alkoxide or inorganic silicate of 0.5 to 2.5, a molar ratio of alcohol to the alkoxide or inorganic silicate is ?0.5; and the sol is either let to gel without induced changes of composition and without forced drying of the sol, or a change of composition is induced; and within a time of ?30 minutes, from the induced change forced drying of the sol is carried out or initiated.

Abstract: This invention relates to a depot formulation comprising a biodegradable silica hydrogel composite incorporating a nucleotide or nucleoside analogue reverse transcriptase inhibitor, wherein the silica hydrogel composite is obtainable by mixing silica particles comprising said nucleotide or nucleoside analogue reverse transcriptase inhibitor and having a maximum diameter of ?1 000 ?m, as such or as a suspension, with silica sol wherein the hydrogel composite is non-flowing and structurally stable when stored at rest and shear-thinning when shear stress is applied by injection. The present invention also relates to use of the depot formulation for treatment of chronic viral infections and prevention of chronic viral reinfection. The present invention further relates to a prefilled syringes comprising said depot formulation.

Abstract: This invention relates to a silica hydrogel composite obtainable by mixing silica particles, comprising an encapsulated agent, with a silica sol, wherein obtained hydrogel composite is shear-thinning. The present invention also relates to use of the silica hydrogel composite according to the invention for an injectable, flowing or extrudable formulation. The present invention further relates to a method for preparing the silica hydrogel.

Abstract: This invention relates to a silica hydrogel composite obtainable by mixing silica particles, comprising an encapsulated agent, with a silica sol, wherein obtained hydrogel composite is shear-thinning. The present invention also relates to use of the silica hydrogel composite according to the invention for an injectable, flowing or extrudable formulation. The present invention further relates to a method for preparing the silica hydrogel.

Abstract: A method for storing a water-soluble undissolved silica-based material, optionally with an incorporated functional agent. The method includes immersing the material in an aqueous liquid phase which is initially saturated with a water-soluble silica-based material which is the same or different than the undissolved silica-based material, such that the undissolved silica-based material does not essentially dissolve into the liquid phase during storage, or the proportion of the amount of the initially undissolved silica-based material to the amount of the liquid phase is such that the liquid phase will be saturated or essentially saturated by a dissolved portion of the water-soluble undissolved silica-based material during storage, which dissolved portion of said water soluble undissolved silica-based material is less than 20%. Also disclosed is a storage package which may preferably be used to store functional agents, delivery devices or implants.

Abstract: A method for producing a flowing silica composition including a sol-gel transfer, where redispersion is carried out. The redispersion includes adding, after having reached gel point of the sol-gel transfer, liquid into the gel formed by the sol-gel transfer, and the addition being made within a sufficiently short time period after reaching the gel point, to result, after mixing of the gel and the liquid, in a rheologically homogenous flowing silica composition, which is and remains injectable as such, or by short stirring <30 s, through a thin 22G needle. Also disclosed are flowing silica compositions and gels obtainable by methods of the invention, and uses of flowing silica compositions.

Abstract: A method for storing a water-soluble undissolved silica-based material, optionally with an incorporated functional agent. The method includes immersing the material in an aqueous liquid phase which is initially saturated with a water-soluble silica-based material which is the same or different than the undissolved silica-based material, such that the undissolved silica-based material does not essentially dissolve into the liquid phase during storage, or the proportion of the amount of the initially undissolved silica-based material to the amount of the liquid phase is such that the liquid phase will be saturated or essentially saturated by a dissolved portion of the water-soluble undissolved silica-based material during storage, which dissolved portion of said water soluble undissolved silica-based material is less than 20%. Also disclosed is a storage package which may preferably be used to store functional agents, delivery devices or implants.

Abstract: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.

Abstract: A method for producing a flowing silica composition including a sol-gel transfer, where redispersion is carried out. The redispersion includes adding, after having reached gel point of the sol-gel transfer, liquid into the gel formed by the sol-gel transfer, and the addition being made within a sufficiently short time period after reaching the gel point, to result, after mixing of the gel and the liquid, in a rheologically homogenous flowing silica composition, which is and remains injectable as such, or by short stirring <30 s, through a thin 22 G needle. Also disclosed are flowing silica compositions and gels obtainable by methods of the invention, and uses of flowing silica compositions.

Abstract: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where said biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in said biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.

Abstract: A biodegradable carrier is produced for preservation and/or controlled delivery of biologically active agents where the biodegradable carrier is a silica xerogel which is made from water and silane by using acid or base as a catalyst, and biologically active agents in the biodegradable carrier are infecting and/or transfecting viruses. Silica xerogel material can be pharmaceutically acceptable and it can be used as a medicine.

Abstract: The present invention relates to a method for preparing a sol-gel derived SiO2 with a very fast bioresorption rate wherein a sol-gel derived SiO2 is prepared from a sol comprising water, an alkoxide or inorganic silicate and a lower alcohol using a mineral acid or a base as a catalyst and said sol is aged and dried. Characteristic for the method is that pH is from 1.5 to 2.5, molar ratio of water to the alkoxide or inorganic silicate is 0.5 to 2.5, of alcohol to the alkoxide or inorganic silicate is ?0.5; and the sol is either let to gel without induced changes of composition and without forced drying of the sol, or a change of composition are induced; and within a time of ?30 minutes, from the induced change forced drying of the sol is carried out or initiated. The present invention also relates to a method for adjusting the bioresorption rate of sol-gel derived SiO2.

Abstract: A method and device for characterizing the compaction result of a powder and monitoring the compaction of the powder during the compaction process. In the method sound emission produced by the compaction process is measured by a sensor and transformed into a frequency spectrum in which the sound intensity is presented as a function of frequency. The intensity of the band relating to the sound emission arising from the compaction of the powder is recorded using different compressive forces, and the compaction result is obtained as a function of the intensity of the band relating to the sound emission arising from compaction.

Abstract: This invention relates to a transdermal preparation comprising a therapeutically active compound of the formula: ##STR1## where R.sub.1, R.sub.2, and R.sub.3, which can be the same or different are H, CH.sub.3, C.sub.2 H.sub.5 or Cl; X is CH.dbd.CH or (CH.sub.2).sub.n where n is 1 to 3 or X is --C(OR.sub.5)H-- where R.sub.5 is methyl or ethyl; and R.sub.4 is hydrogen or a straight alkyl of 1 to 4 carbon atoms. The transdermal administration of the compounds can be accomplished by preparations in the form of ointments, emulsions, lotions, solutions, creams or transdermal patches.

Abstract: Salts of medetomidine and optically active enantiomers, thereof, particularly the d-enantiomer are disclosed. These salts may be used to regulate the rate of the transdermal administration of active drugs. The transdermal delivery system comprises a drug impermeable backing layer and an adhesive layer wherein the medetomidine is dispersed throughout the adhesive layer.

Abstract: Transdermal administration of dexmedetomidine, the dextrorotatory isomer of medetomidine, is described. The method involves sedating a patient by administering dexmedetomidine to a predetermined area of skin at an administration rate and for a time period effective to achieve the desired level of sedation. A therapeutic system for transdermally administering the drug is also provided. The therapeutic system is in the form of a skin patch which is a laminated composite of a backing layer, an optional anchor adhesive layer, a contact adhesive layer, and one or more additional layers.

Abstract: Transdermal administration of dexmedetomidine, the dextrorotatory isomer of medetomidine, is described. The method involves sedating a patient by administering dexmedetomidine to a predetermined area of skin at an administration rate and for a time period effective to achieve the desired level of sedation. A therapeutic system for transdermally administering the drug is also provided. The therapeutic system is in the form of a skin patch which is a laminated composite of a backing layer, an optional anchor adhesive layer, a contact adhesive layer, and one or more additional layers.